INSPIRIS RESILIA Valve in Pulmonary Position

Last updated: October 13, 2022
Sponsor: Medical University of Vienna
Overall Status: Active - Recruiting

Phase

N/A

Condition

Congenital Heart Disease

Heart Disease

Pentalogy Of Cantrell

Treatment

N/A

Clinical Study ID

NCT05583656
1888/2018
  • Ages 5-99
  • All Genders

Study Summary

In this trial we intend to evaluate the safety and effectiveness of the INSPIRIS valve prothesis in the pulmonary position in patients of five years or older, with congenital or acquired pulmonary valve disease, requiring replacement of their native or prosthetic pulmonary valve.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. pulmonary valve disease requiring pulmonary valve replacement of their native orprosthetic valve, equal to or greater than five years of age.
  2. Patients and/or patient´s legal representatives must provide written informed consentas approved and required by the respective institutional review board and agree to itsprovisions.
  3. The patient has completed all preoperative investigations.

Exclusion

Exclusion Criteria:

  1. Requires emergency surgery
  2. Has acute myocardial infarction (MI) within 30 days prior to screening date
  3. Has MRI or CT scan confirmed stroke, cerebrovascular accident (CVA) or transientischemic attack (TIA) within six months prior to screening date
  4. Has hemodynamic or respiratory instability requiring inotropic support, mechanicalcirculatory support, or mechanical ventilation within 30 days prior to screening date
  5. Has active endocarditis/myocarditis or endocarditis/myocarditis within three monthsprior to screening date
  6. Has renal insufficiency as determined by creatinine level ≥ 2.5 mg/dL within 60 daysprior to screening visit or end-stage renal disease
  7. Has documented:
  8. leukopenia (WBC < 3.5x 103/µL),
  9. acute anemia (Hgb<10.0 g/dL or 6 mmol/L), or
  10. thrombocytopenia (platelet count < 50x 103/µL) accompanied by history of bleedingdiathesis or coagulopathy within 60 days prior screening date
  11. Diagnosed with abnormal calcium metabolism and/or hyperparathyroidism 10.Echocardiographic evidence of an intra-cardiac mass, thrombus, or vegetation 11. RVOTaneurysm unless treated during pulmonary valve replacement surgery 12. Has prior organtransplant or is currently an organ transplant candidate 13. Was previously implanted withstudy trial device 14. Previously implanted with an aortic, mitral, or tricuspidbioprosthetic valve or mechanical valve 16. Has presence of non-cardiac disease limitinglife expectancy to less than 12 months 17. Is currently or has recently participated (within six weeks) in another investigational drug or device trial 18. Positive urine orserum pregnancy test in female subjects of child-bearing potential and/or nursing mothers
  12. Currently incarcerated or unable to give voluntary informed consent 21. Documentedhistory of substance (drug or alcohol) abuse within the last five years prior to screeningdate

Study Design

Total Participants: 40
Study Start date:
August 12, 2019
Estimated Completion Date:
February 01, 2024

Study Description

Up to 40 subjects will be invited to participate in this trial after the indication for pulmonary valve replacement has been established. At the inclusion visit, patients will be screened according to the inclusion / exclusion criteria. After written informed consent, a detailed history will be obtained, and the study related exams will be performed.

The procedure will be performed through a median sternotomy with the help of cardiopulmonary bypass in a beating or arrested heart fashion depending on the individual surgeon's discretion. Any additional or residual defects will concomitantly be addressed. Either a native or prosthetic pulmonary valve will be replaced by an Edwards Inspiris valve (Edwards Lifesciences, Unterschleissheim, Germany). If a conduit is required, the valve will be sewn into a suitable prosthesis beforehand.

Subjects will be seen regularly after pulmonary valve implantation at hospital discharge, 6-month, 1 year and 2 years after surgery. A cardiac magnetic resonance imaging will be performed at inclusion and 2 years after surgery.

Total enrollment period for the study is estimated to be two years. The trial starts with the enrollment of the first patients and ends after the last patient enrolled has completed the two-year visit or has exited the study.

Connect with a study center

  • Medical University of Vienna

    Vienna, 1090
    Austria

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.